The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Feb 2016
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Cachexia
- Focus Therapeutic Use
- 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Apr 2015 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov.
- 02 Apr 2015 Planned primary completion date changed to 1 Apr 2017 as reported by ClinicalTrials.gov.